Concepedia

Rosalie Odchimar-Reissig

RO

11

Publications

2.7K

Citations

11

H-Index

2002

Active since

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

Onconova Therapeutics (United States)

National Cancer Institute

The University of Texas MD Anderson Cancer Center

Albert Einstein College of Medicine

Rosalie Odchimar-Reissig is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, pharmacotherapy, and hematology.

Top concepts

Publications per year

2002–2020

11

Publications

11

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

Alice B. Kornblith, James E. Herndon, Lewis R. Silverman et al. · Journal of Clinical Oncology · 2002 · 415 citations

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Tamer E. Fandy, James G. Herman, Patrick Kerns et al. · Blood · 2009 · 286 citations · Full text

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Lewis R. Silverman, Amit Verma, Rosalie Odchimar-Reissig et al. · Blood · 2008 · 49 citations

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

Shyamala Navada, Steven Fruchtman, Rosalie Odchimar-Reissig et al. · Leukemia Research · 2017 · 42 citations

, , +7

Rows per page

1–5 of 11